Oppenheimer & CO Inc Prothena Corp Public LTD CO Transaction History

Oppenheimer & CO Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$32.31 - $52.32 $51,114 - $82,770	-1,582 Reduced 20.01%	6,326 $229,000
Q3 2023 Nov 07, 2023	BUY	$47.3 - $70.6 $13,953 - $20,827	295 Added 3.87%	7,908 $381,000
Q2 2023 Aug 02, 2023	BUY	$48.26 - $78.59 $16,553 - $26,956	343 Added 4.72%	7,613 $519,000
Q1 2023 May 10, 2023	BUY	$46.97 - $58.27 $341,471 - $423,622	7,270 New	7,270 $352,000
Q1 2022 May 12, 2022	SELL	$30.27 - $49.22 $137,698 - $223,901	-4,549 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$42.11 - $73.26 $9,011 - $15,677	-214 Reduced 4.49%	4,549 $225,000
Q3 2021 Nov 12, 2021	BUY	$48.2 - $78.89 $229,576 - $375,753	4,763 New	4,763 $339,000
Q4 2018 Jan 29, 2019	SELL	$8.73 - $13.74 $93,454 - $147,086	-10,705 Closed	0 $0
Q3 2018 Oct 26, 2018	SELL	$12.7 - $15.79 $9,525 - $11,842	-750 Reduced 6.55%	10,705 $140,000
Q2 2018 Aug 10, 2018	BUY	$10.99 - $44.21 $40,663 - $163,577	3,700 Added 47.71%	11,455 $166,000
Q1 2018 May 01, 2018	BUY	$27.95 - $45.04 $216,752 - $349,285	7,755 New	7,755 $284,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.